Advanced search
Publication Cover
OncoImmunology Volume 2, 2013 - Issue 9
Submit an article Journal homepage
690
Views
21
CrossRef citations to date
0
Altmetric
Author's View

Overcoming immunosuppression as a new immunotherapeutic approach against pancreatic cancer

Alexandr V Bazhin Department of General Surgery; University of Heidelberg; Heidelberg, GermanyCorrespondence[email protected]
,
Jagadeesh Bayry INSERM Unité 872; Centre de Recherche des Cordeliers; Paris, France
,
Viktor Umansky Skin Cancer Unit; German Cancer Research Center (DKFZ); Heidelberg and Department of Dermatology; Venereology and Allergology; University Medical Center Mannheim; Ruprecht-Karl University of Heidelberg; Mannheim, Germany
,
Jens Werner Department of General Surgery; University of Heidelberg; Heidelberg, Germany
&
Svetlana Karakhanova Department of General Surgery; University of Heidelberg; Heidelberg, Germany
Article: e25736 | Received 10 Jul 2013, Accepted 11 Jul 2013, Published online: 23 Jul 2013

References

  • Cress RD, Yin D, Clarke L, Bold R, Holly EA. Survival among patients with adenocarcinoma of the pancreas: a population-based study (United States). Cancer Causes Control 2006; 17:403 - 9; http://dx.doi.org/10.1007/s10552-005-0539-4; PMID: 16596292
  • Rosty C, Goggins M. Early detection of pancreatic carcinoma. Hematol Oncol Clin North Am 2002; 16:37 - 52; http://dx.doi.org/10.1016/S0889-8588(01)00007-7; PMID: 12063828
  • Ryschich E, Nötzel T, Hinz U, Autschbach F, Ferguson J, Simon I, et al. Control of T-cell-mediated immune response by HLA class I in human pancreatic carcinoma. Clin Cancer Res 2005; 11:498 - 504; PMID: 15701833
  • Heller A, Zörnig I, Müller T, Giorgadze K, Frei C, Giese T, et al. Immunogenicity of SEREX-identified antigens and disease outcome in pancreatic cancer. Cancer Immunol Immunother 2010; 59:1389 - 400; http://dx.doi.org/10.1007/s00262-010-0870-9; PMID: 20514540
  • Schmidt J, Jäger D, Hoffmann K, Büchler MW, Märten A. Impact of interferon-alpha in combined chemoradioimmunotherapy for pancreatic adenocarcinoma (CapRI): first data from the immunomonitoring. J Immunother 2007; 30:108 - 15; http://dx.doi.org/10.1097/01.cji.0000211317.15278.27; PMID: 17198089
  • Schmidt J, Abel U, Debus J, Harig S, Hoffmann K, Herrmann T, et al. Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma. J Clin Oncol 2012; 30:4077 - 83; http://dx.doi.org/10.1200/JCO.2011.38.2960; PMID: 23008325
  • Shevchenko I, Karakhanova S, Soltek S, Link J, Bayry J, Werner J, et al. Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer. Int J Cancer 2013; 133:98 - 107; http://dx.doi.org/10.1002/ijc.27990; PMID: 23233419
  • Loos M, Giese NA, Kleeff J, Giese T, Gaida MM, Bergmann F, et al. Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer. Cancer Lett 2008; 268:98 - 109; http://dx.doi.org/10.1016/j.canlet.2008.03.056; PMID: 18486325
  • Sistigu A, Viaud S, Chaput N, Bracci L, Proietti E, Zitvogel L. Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin Immunopathol 2011; 33:369 - 83; http://dx.doi.org/10.1007/s00281-011-0245-0; PMID: 21611872
  • Meyer C, Sevko A, Ramacher M, Bazhin AV, Falk CS, Osen W, et al. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc Natl Acad Sci U S A 2011; 108:17111 - 6; http://dx.doi.org/10.1073/pnas.1108121108; PMID: 21969559

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.